NCT01425229View on ClinicalTrials.gov

Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin

CompletedOBSERVATIONAL
Enrollment

16

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

December 31, 2012

Conditions
Drug Interactions
Interventions
DRUG

Bosentan

"* Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14~* Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"

Trial Locations (1)

Unknown

University Hospital Heidelberg, Heidelberg

All Listed Sponsors
lead

Gerd Mikus

OTHER

NCT01425229 - Influence of OATP1B1 and CYP2C9 Genotypes on the Pharmacokinetics of Bosentan Before and During Clarithromycin | Biotech Hunter | Biotech Hunter